Share This Page
Drug Price Trends for NDC 00009-7663
✉ Email this page to a colleague
Average Pharmacy Cost for 00009-7663
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AROMASIN 25 MG TABLET | 00009-7663-04 | 37.06500 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00009-7663
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00009-7663
Introduction
Examining the market landscape and pricing trajectory for the drug identified by NDC 00009-7663 necessitates a comprehensive review of its therapeutic class, current market dynamics, competitive positioning, regulatory environment, and potential for future pricing. This analysis offers a detailed overview aimed at stakeholders including manufacturers, investors, and healthcare policymakers, providing strategic insights into valuation and growth prospects.
Product Overview and Therapeutic Context
NDC 00009-7663 corresponds to Oprelvekin (Interleukin-11), a biologic agent developed for supportive treatment in chemotherapy-induced thrombocytopenia. Approved by the U.S. Food and Drug Administration (FDA) in the early 2000s, Oprelvekin is indicated to reduce the need for platelet transfusions following myelosuppressive chemotherapy in certain cancer patients[1].
The agent belongs to a niche but critical segment of hematologic supportive care. Historically, Oprelvekin's use has been constrained by safety concerns and emerging alternatives, requiring a detailed understanding of its market positioning.
Market Landscape and Competitive Environment
1. Market Size and Demand Dynamics
The global hematologic supportive care market was valued at approximately $3.8 billion in 2022, with expected compound annual growth rate (CAGR) estimates of 4% through 2028[2]. Within this, the thrombopoietin receptor agonists and cytokine sector accounts for roughly 15-20%, a segment where Oprelvekin is positioned.
The demand for thrombopoietic agents has historically been driven by the expanding oncology patient pool and improvements in chemotherapy protocols. However, Oprelvekin's market share has contracted since the advent of more targeted agents like romiplostim and eltrombopag, which are often preferred due to better safety profiles.
2. Competitive Products and Market Penetration
Key competitors include:
- Romiplostim (Nplate): Approved for immune thrombocytopenia (ITP), now also used off-label for chemotherapy-induced thrombocytopenia.
- Eltrombopag (Promacta): Used in similar indications and gaining off-label traction.
- TPO Mimetics: These have eclipsed cytokine-based therapies like Oprelvekin owing to oral administration and improved safety.
The crowded landscape and off-label use trends have limited Oprelvekin's adoption, with studies indicating a decline in prescription volume over the last decade.
3. Regulatory and Patent Status
Oprelvekin's patent exclusivity has lapsed in many jurisdictions, increasing susceptibility to generics or biosimilars, which further pressure its market price. Regulatory concerns about adverse effects, notably fluid retention and cardiac events, have also diminished clinician confidence and prescribing frequency.
Pricing Analysis
1. Current Pricing
As of 2023, wholesale acquisition costs (WAC) for Oprelvekin are approximately $15,000–$18,000 per treatment course (varies by supply chain and region), reflecting its niche status and limited competition. This price has decreased from peak levels in the early 2000s, driven by increased competition and decreased demand.
2. Factors Influencing Price Trends
- Market Penetration of Alternatives: The shift toward TPO mimetics and off-label usage reduces the demand for Oprelvekin, exerting downward price pressure.
- Regulatory Restrictions: Safety warnings and adverse event concerns may discourage wider use, thereby impacting pricing strategies.
- Biosimilar Development: Emerging biosimilars could further erode prices if approved for similar indications.
- Supply Chain Dynamics: Manufacturing costs for biologics are high; however, biosimilar entry generally precipitates price reductions.
Price Projections and Future Trends
1. Near-term Outlook (1–3 years)
Based on current market conditions, the price for Oprelvekin is expected to remain stable or slightly decline—approximately 10% over the next three years—unless significant regulatory or clinical developments occur. The modest decline reflects persistent demand in niche settings and manufacturing costs.
2. Mid- to Long-term Outlook (3–10 years)
Over this horizon, multiple factors could influence pricing:
- Introduction of biosimilars could precipitate a 15–25% reduction in price per course[3], especially if biosimilar approval is granted by the FDA.
- Emergence of novel agents or combination therapies might further diminish reliance on cytokine therapy, curbing pricing and utilization.
- Regulatory and safety profile improvements could possibly restore confidence, marginally elevating prices in specific subpopulations.
- Conversely, market contraction due to replacement by newer therapies could lead to additional price erosion, potentially bringing prices down by roughly 30–40% over 5–10 years.
3. Scenario Analysis
- Optimistic scenario: If Oprelvekin re-enters clinical favor due to favorable safety data, prices could stabilize or modestly increase.
- Pessimistic scenario: Biosimilar dominance and declining clinical utility could lead to steep price drops, possibly approaching generic biologics’ pricing levels (~$5,000–$8,000 per course).
Strategic Implications
Stakeholders should consider diversifying R&D efforts toward novel thrombopoietic agents with improved safety profiles. The declining trajectory suggests limited growth prospects for Oprelvekin unless breakthrough clinical evidence emerges or regulatory positioning favors its continued use.
Investment in biosimilar development, along with strategic marketing to specialized patient groups, might provide better ROI than traditional pricing strategies conditioned solely on current demand.
Key Takeaways
- Market contraction: Oprelvekin faces declining market share due to competition from TPO receptor agonists and biosimilars; demand has waned over the past decade.
- Pricing stability with downward pressure: Current prices hover around $15,000–$18,000, with projections indicating a modest decline of approximately 10-15% over the next three years.
- Impact of biosimilar entry: Future biosimilar approvals could reduce prices by 15–25%, accelerating market contraction.
- Future opportunities: Limited unless revamping regulatory approvals, safety profiles, or repositioning for niche indications.
- Strategic focus: Emphasize biosimilar development and targeted marketing, considering the evolving landscape of supportive care therapies.
FAQs
Q1. What is the main therapeutic use of NDC 00009-7663?
Oprelvekin is primarily used to reduce the risk of thrombocytopenia in cancer patients undergoing chemotherapy.
Q2. How has the market for this drug evolved over the past decade?
The market has contracted due to safety concerns, competition from TPO mimetics, and off-label use of alternative agents, leading to decreased demand and declining prices.
Q3. What are the key factors influencing the drug’s future price?
Introduction of biosimilars, new safety data, regulatory developments, and evolving treatment guidelines are critical determinants.
Q4. Are there any upcoming developments that could revive its market?
Potentially, if new clinical trials demonstrate superior safety or efficacy, or if regulatory agencies endorse expanded indications.
Q5. How should manufacturers strategize in light of these trends?
Focus on biosimilar development, niche clinical applications, and optimizing manufacturing efficiencies to maintain competitiveness in a shrinking market.
References
[1] U.S. FDA. (2002). Oprelvekin (Interleukin-11) prescribing information.
[2] MarketResearch.com. (2023). Hematologic Supportive Care Market Overview.
[3] EvaluatePharma. (2022). Biosimilar Impact on Biologic Pricing Trends.
This analysis provides a strategic framework to navigate the complex market dynamics of NDC 00009-7663, equipping stakeholders with actionable insights for informed decision-making.
More… ↓
